Immunovant Files 10-Q for Q3 FY2025
Ticker: IMVT · Form: 10-Q · Filed: Feb 6, 2025 · CIK: 1764013
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
IMVT 10-Q filed for 12/31/24. Financials updated.
AI Summary
Immunovant, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the three and nine months ended December 31, 2024, and compares them to the same periods in 2023. Key financial data and business updates are provided, though specific dollar amounts for revenue, expenses, or net income are not detailed in this excerpt.
Why It Matters
This filing provides investors with an update on Immunovant's financial performance and operational status for the third quarter of fiscal year 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — The filing is a standard 10-Q, but the biotech sector inherently carries higher risks due to clinical trial outcomes and regulatory approvals.
Key Numbers
- 2024-12-31 — Period End Date (Indicates the end of the reporting quarter)
- 2025-02-06 — Filing Date (Date the 10-Q was officially submitted)
Key Players & Entities
- Immunovant, Inc. (company) — Filer of the 10-Q
- 2024-12-31 (date) — End of the reporting period
- 2025-02-06 (date) — Filing date
- Health Sciences Acquisitions Corp (company) — Former company name
FAQ
What were Immunovant's total revenues for the three months ended December 31, 2024?
The provided excerpt does not contain specific figures for total revenues for the three months ended December 31, 2024.
What was the net loss for Immunovant for the nine months ended December 31, 2024?
Specific net loss figures for the nine months ended December 31, 2024, are not detailed in this excerpt.
When did Immunovant change its name from Health Sciences Acquisitions Corp?
Immunovant, Inc. changed its name from Health Sciences Acquisitions Corp on January 8, 2019.
What is Immunovant's fiscal year end?
Immunovant's fiscal year ends on March 31.
What is the SIC code for Immunovant, Inc.?
The Standard Industrial Classification (SIC) code for Immunovant, Inc. is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 4,633 words · 19 min read · ~15 pages · Grade level 16 · Accepted 2025-02-06 06:45:11
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Sto
Filing Documents
- imvt-20241231.htm (10-Q) — 1292KB
- exhibit101-20241231q3.htm (EX-10.1) — 69KB
- exhibit311-20241231q3.htm (EX-31.1) — 10KB
- exhibit312-20241231q3.htm (EX-31.2) — 10KB
- exhibit321-20241231q3.htm (EX-32.1) — 4KB
- exhibit322-20241231q3.htm (EX-32.2) — 4KB
- imvt-20241231_g1.jpg (GRAPHIC) — 143KB
- imvt-20241231_g2.jpg (GRAPHIC) — 152KB
- 0001764013-25-000026.txt ( ) — 5811KB
- imvt-20241231.xsd (EX-101.SCH) — 28KB
- imvt-20241231_cal.xml (EX-101.CAL) — 39KB
- imvt-20241231_def.xml (EX-101.DEF) — 198KB
- imvt-20241231_lab.xml (EX-101.LAB) — 464KB
- imvt-20241231_pre.xml (EX-101.PRE) — 334KB
- imvt-20241231_htm.xml (XML) — 394KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements (unaudited)
Item 1. Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets as of December 31, 2024 and March 31, 2024 4 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2024 and 2023 5 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended December 31, 2024 and 2023 6 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended December 31, 2024 and 2023 7 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2024 and 2023 8 Notes to Condensed Consolidated Financial Statements 9
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 33
Controls and Procedures
Item 4. Controls and Procedures 33
OTHER INFORMATION
PART II. OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings 34
Risk Factors
Item 1A. Risk Factors 34
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 86
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 86
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 86
Other Information
Item 5. Other Information 86
Exhibits
Item 6. Exhibits 87
SIGNATURES
SIGNATURES 88 Where You Can Find More Information Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (www.immunovant.com), filings we make with the Securities and Exchange Commission, webcasts, press releases, and conference calls. We use these mediums, including our website, to communicate with our stockholders and the public about our company, our product candidates, and other matters. It is possible that the information that we make available may be deemed to be material information. We therefore encourage investors and others interested in our company to review the information that we make available on our website. The information contained on the website referenced in this Quarterly Report on Form 10-Q is not incorporated by reference into this filing, and the website address is provided only as an inactive textual reference. All trademarks, trade names, service marks, and copyrights appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. 1 Table of Contents SUMMARY RISK FACTORS You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to "we," "us," and "our" in this section titled "Summary Risk Factors" refer to Immunovant, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: Our business is currently dependent on the successful and timely development, regulatory approval and commercialization of our product candidates. Our product candidates, or anti-FcRn product candidates or products developed by others, may cause adverse events or undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical t
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements IMMUNOVANT, INC. Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share data) December 31, 2024 March 31, 2024 Assets Current assets: Cash and cash equivalents $ 374,685 $ 635,365 Accounts receivable 2,224 5,337 Prepaid expenses and other current assets 35,632 25,068 Total current assets 412,541 665,770 Operating lease right-of-use assets 22 133 Other assets 7,617 — Property and equipment, net 752 462 Total assets $ 420,932 $ 666,365 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 19,816 $ 7,155 Accrued expenses 48,476 41,315 Current portion of operating lease liabilities 23 138 Total current liabilities 68,315 48,608 Total liabilities 68,315 48,608 Commitments and contingencies (Note 9) Stockholders' equity: Series A preferred stock, par value $ 0.0001 per share, 10,000 shares authorized, issued and outstanding at December 31, 2024 and March 31, 2024 — — Preferred stock, par value $ 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and March 31, 2024 — — Common stock, par value $ 0.0001 per share, 500,000,000 shares authorized, 147,203,565 shares issued and outstanding at December 31, 2024 and 500,000,000 shares authorized, 145,582,999 shares issued and outstanding at March 31, 2024 14 14 Additional paid-in capital 1,483,198 1,441,518 Accumulated other comprehensive income 2,479 1,908 Accumulated deficit ( 1,133,074 ) ( 825,683 ) Total stockholders' equity 352,617 617,757 Total liabilities and stockholders' equity $ 420,932 $ 666,365 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents IMMUNOVANT, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Oper